Mineralys Therapeutics, Inc. Q1 FY2026 earnings call

John Congleton began by overviewing the business, clinical programs, and recent milestones. The FDA accepted the NDA for lorunderstat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs and assigned a PDUFA target date of December 22, 2026. Operational focus is on preparing lorunderstat for a successful launch in the US, evaluating partnering opportunities, and considering next steps in clinical development. Adam Levy then reviewed first quarter financial results, noting cash, R&D, G&A expenses, other income net, and net loss figures.

Cash, cash equivalents, and investments ended the quarter at $646.1 million as of March 31, 2026, down from $656.6 million as of December 31, 2025. R&D expenses for the quarter ended March 31, 2026 were $24.4 million, down from $37.9 million in the same quarter of 2025. G&A expenses were $21 million for the quarter ended March 31, 2026, up from $6.6 million in the same quarter of 2025. Total other income net was $6 million for the quarter ended March 31, 2026, up from $2.2 million in the same quarter of 2025. Net loss was $39.3 million for the quarter ended March 31, 2026, down from $42.2 million in the same quarter of 2025.

The company believes current cash, cash equivalents, and investments will be sufficient to fund planned clinical trials and regulatory activities, as well as support corporate operations into 2028. They continue to evaluate partnering opportunities and are focused on preparing lorunderstat for a strong commercial launch.

Questions and answers included discussions on launch plans without a partner, safety of lorunderstat, payer access and strategy, partnering opportunities, physician segmentation, guideline changes, differentiation, pricing, commercial analogs, and launch cadence